This product is a statin blood lipid regulating drug, belonging to the HMG-CoA reductase inhibitor. It is inactive itself, and the hydrolysis product after oral absorption competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. It has a carcinogenic effect on some animals.

External use has anti-inflammatory, anti-allergic, antipruritic and exudation reducing effects

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

This product is a glucocorticoid drug, which has anti-inflammatory, anti-allergic, antipruritic and exudation-reducing effects when used externally.

Proton pump inhibitor. This product is a fat-soluble weakly alkaline drug that is easily concentrated in an acidic environment. Therefore, after oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells and converted into the active form of sulfenamide in this high-acid environment. It then irreversibly combines with the sulfhydryl group of the H, K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons.

Increases the synthesis of GABA and reduces its degradation, raising the concentration of the inhibitory neurotransmitter g-aminobutyric acid (GABA), reducing the excitability of neurons and inhibiting seizures; it can produce an inhibitory effect on Na channels similar to phenytoin. It is harmful to the liver.